News
DRMAW
0.0177
+1.14%
0.0002
Weekly Report: what happened at DRMAW last week (0602-0606)?
Weekly Report · 3d ago
Weekly Report: what happened at DRMAW last week (0526-0530)?
Weekly Report · 06/02 11:52
Weekly Report: what happened at DRMAW last week (0519-0523)?
Weekly Report · 05/26 11:52
DERMATA THERAPEUTICS INC - POTENTIAL NDA FILING FOR XYNGARI IN H1 2028 - SEC FILING
Reuters · 05/21 13:02
Weekly Report: what happened at DRMAW last week (0512-0516)?
Weekly Report · 05/19 11:40
Weekly Report: what happened at DRMAW last week (0505-0509)?
Weekly Report · 05/12 11:41
Weekly Report: what happened at DRMAW last week (0428-0502)?
Weekly Report · 05/05 11:43
Weekly Report: what happened at DRMAW last week (0421-0425)?
Weekly Report · 04/28 11:55
Weekly Report: what happened at DRMAW last week (0414-0418)?
Weekly Report · 04/21 11:54
Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference At 4 Weeks
Benzinga · 04/15 12:42
DERMATA THERAPEUTICS INC - ANNOUNCES TOPLINE RESULTS FROM PHASE 3 TRIAL OF XYNGARI - SEC FILING
Reuters · 04/15 12:32
Weekly Report: what happened at DRMAW last week (0407-0411)?
Weekly Report · 04/14 11:41
Weekly Report: what happened at DRMAW last week (0331-0404)?
Weekly Report · 04/07 11:41
Weekly Report: what happened at DRMAW last week (0324-0328)?
Weekly Report · 03/31 11:55
BUZZ-U.S. STOCKS ON THE MOVE-Rigel Pharma, Concentrix, Avis Budget
Reuters · 03/27 15:45
DERMATA THERAPEUTICS SHARES UP 68% AS ACNE TREATMENT SUCCEEDS LATE-STAGE STUDY
Reuters · 03/27 13:33
BUZZ-U.S. STOCKS ON THE MOVE-Lockheed Martin, New Fortress Energy, Northrop Grumman
Reuters · 03/27 13:25
BUZZ-Dermata Therapeutics rises after positive late-stage study data of acne treatment
Reuters · 03/27 12:32
DERMATA THERAPEUTICS INC - TO INITIATE SECOND PHASE 3 TRIAL FOR XYNGARI IN H2 2025
Reuters · 03/27 12:00
Weekly Report: what happened at DRMAW last week (0317-0321)?
Weekly Report · 03/24 11:41
More
Webull provides a variety of real-time DRMAW stock news. You can receive the latest news about Dermata Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DRMAW
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.